Drugs / CNDO-109-AANK Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01520558 | Dec 2012 → Mar 2016 | acute myeloid leukemia | Coronado Biosciences, Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CNDO-109-AANK Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01520558 ↗ |
| Modality | Cell therapy | “CNDO-109-Activated Allogeneic Natural Killer Cells” NCT01520558 ↗ |